
science & pipeline
Jump to Pipelineour product platform
Our drug engineering platform leverages and efficiently translates innovation into therapies that matter.

discover novel genetic disease targets
Well described diseases that can be targeted at their source
- Our genetic disease target engine allows us to identify genetic diseases to pursue based on the impact we might deliver for patients
- We use computational genomics and statistical genetics, along with systematic disease mapping and partnerships with top academic institutions to identify potential disease-modifying targets
- Our team is made up of industry leaders with proven track records who bring decades of scientific insight to the table when selecting genetic disease targets for our pipeline

create medicines with our industry research capabilities
Tailored therapeutic technologies that create potential first or best-in-class medicines
- We select a therapeutic approach to target each genetic disease at its source
- Our capabilities allow us to work across multiple modalities, including molecular dynamics assisted chemistry, gene therapy, therapeutic proteins and antisense oligonucleotides as well as multiple other technologies, including de novo QGS, NMR trapping and molecular dynamics
- Our small, expert teams led by industry veterans focus on addressing the greatest unmet patient needs. We pair each disease with the modality that is suited to maximize patient impact

test our drugs through global development footprint
Broad clinical development capabilities across therapeutic areas and geographies
- We have a global clinical development footprint
- We have ongoing trials across five different therapeutic areas and over 25 countries
- Our patient-centric clinical and regulatory strategies are focused on efficiency and speed and deploys our vast experience across enrollment, protocol quality, site activation, CRO quality and regional performance
- We have expert, dedicated R&D teams in each therapeutic area and focused scientific and clinical advisors to guide our programs

deliver our products to patients through commercial infrastructures
Capabilities built to deliver genetic medicines to patients globally
- We are building the capabilities and collaborating with partners to deliver our approved products to patients across the globe
- We look for new diagnostic partnerships to identify more patients in need of our medicines
- We are committed to deepening the early partnerships we have built with patient advocacy groups
- We are implementing commercial partnerships in strategic geographics and establishing country-specific Early Access Programs (EAP) and patient assistance programs
We are poised to potentially help 4.5m+ patients across our pipeline
Our platform is delivering:
2approved products
30+programs in our pipeline
30+clinical trials across the globe
The Pipeline
Precision cardiorenal targets genetically-validated mechanisms underlying heart and kidney disease.
Pre-clinical
Phase 1
Phase 2
Phase 3
Commercial
Mendelian diseases arise from defects in a single gene.
Pre-clinical
Phase 1
Phase 2
Phase 3
Commercial
Precision oncology targets clear genetic aberrations that drive cancer.
Pre-clinical
Phase 1
Phase 2
Phase 3
Commercial
Gene therapy aims to replace functional copies of single genes harboring loss-of-function mutations. Genetic material is delivered into cells via non-replicating virus particles, offering the potential for one-time, curative therapy.
Pre-clinical
Phase 1
Phase 2
Phase 3
Commercial
Visit publications for selected literature and presentations for recent data presented at medical meetings about each program.
our commitment to patients
BridgeBio ultimately exists to help patients. We are committed to discover, create, test and deliver breakthrough medicines for genetic diseases to patients as quickly and safely as possible.